Treatment with Dendritic Cells Leads to Long-Term Mesothelioma Survival in Small Studies
Three small studies suggest that dendritic cells may offer a new, more promising way to fight malignant pleural mesothelioma. Dendritic cells are immune system cells that function as messengers. They are supposed to signal T-cells to attack cancers like malignant mesothelioma. But mesothelioma cells can keep dendritic cells from doing their job. The result is that the number of activated T-cells around mesothelioma tumors stays low and the tumors keep growing. Now, Dutch researchers studying the problem say a vaccine made from dendritic cells may hold the answer. They analyzed the results of three small dendritic cell studies. These studies included a total of 29 mesothelioma patients. Some of the patients in these studies lived much longer than mesothelioma patients normally … Continue reading Treatment with Dendritic Cells Leads to Long-Term Mesothelioma Survival in Small Studies
Risk of Mesothelioma in Women May be Underestimated
An international team of occupational health experts says science has done a “profound disservice” by underestimating the risk of mesothelioma in women. Scientists from Germany, Canada, Italy, and the US compiled the report for the American Journal of Industrial Medicine. They say the risk of mesothelioma in women has long been misunderstood. Asbestos is the main cause of mesothelioma in men. But the new report says studies often fail to link female mesothelioma cases to asbestos exposure. That omission made some believe that the risk of mesothelioma in women is different than it is in men. But the new report says that is not true. It urges scientists to be more thorough in their mesothelioma studies of women. Asbestos and … Continue reading Risk of Mesothelioma in Women May be Underestimated
Higher PD-L1 Protein May Predict Shorter Mesothelioma Survival
Mesothelioma patients with higher levels of the PD-L1 protein in their tumor cells have worse overall survival compared to those with lower levels. But that may not be true for patients who have immunotherapy. That news comes from a new European study of more than 200 patients. PD-L1 and its partner protein PD-1 (found in immune system cells) are popular targets for new immunotherapy drugs. But the new study aimed to find out if they impact mesothelioma survival independently of immunotherapy. The team concluded the PD-L1 protein may shorten lifespan. PD-1 does not seem to have the same effect. Pleural Mesothelioma and the PD-L1 Protein Pleural mesothelioma is an intractable cancer of the lung lining. It often leads to poor … Continue reading Higher PD-L1 Protein May Predict Shorter Mesothelioma Survival
Different Mesothelioma Subtypes: Gene Study Could Lead to Targeted Treatments
A group of European pathologists say the different mesothelioma subtypes have significant differences in their pattern of gene expression. Exploiting these differences could help scientists craft more effective mesothelioma treatments. Asbestos exposure is the primary cause of mesothelioma. But doctors know that genetics play a role, too. Newly-approved immunotherapy drugs target proteins expressed by specific genes. But these drugs work much better in some mesothelioma patients than they do in others. The new study suggests that differences in the genetic profiles of different mesothelioma subtypes could help explain why. Immunotherapy Drugs for Mesothelioma Immunotherapy is an up-and-coming treatment approach for mesothelioma and other cancers. It harnesses the power of the person’s immune system to fight cancer. In people with mesothelioma, … Continue reading Different Mesothelioma Subtypes: Gene Study Could Lead to Targeted Treatments
Treatment Advances Fail to Improve Mesothelioma Survival Trends
A new report shows mesothelioma survival trends have remained steady for decades, despite new drugs, new surgery techniques, and the introduction of pleural catheters. The report comes from cancer researchers at Ottawa Hospital Cancer Centre in Canada. Canada has one of the world’s highest rates of malignant pleural mesothelioma. This is likely related to the country’s long history of asbestos production. To compile the new report, researchers compared mesothelioma outcomes in three different decades between 1991 and 2019. There were surprisingly few differences in mesothelioma survival trends in the three decades. Mesothelioma’s Destructive History Pleural mesothelioma is a virulent cancer of the pleural membrane. This is the tissue or mesothelium that surrounds the lungs. It is thin but flexible and … Continue reading Treatment Advances Fail to Improve Mesothelioma Survival Trends
Long-Term Mesothelioma Survival With Immunotherapy Combination
An immunotherapy combination of tremelimumab and durvalumab has resulted in long-term survival for some mesothelioma patients in a new follow-up Italian study. Tremelimumab and durvalumab (Imfinzi) received orphan drug designation from the FDA last year for liver cancer. Now, it looks like this immunotherapy combination could help some people with the rare asbestos cancer, too. Mesothelioma patients who had the best results in the new study were those with a high number of mutated genes. Mesothelioma is often fatal within a year. But the longest-living patient in the study survived for more than 41 months. Immunotherapy Combination Blocks Key Proteins White blood cells have the power to help combat mesothelioma. But a protein called CTLA-4 can block that ability. Tremelimumab … Continue reading Long-Term Mesothelioma Survival With Immunotherapy Combination
CRS/HIPEC Procedure Has Improved Over Time, Study Finds
A new French study contains some good news for people considering the CRS/HIPEC procedure for peritoneal mesothelioma. The CRS/HIPEC procedure combines surgical resection with localized chemotherapy. Its aim is to remove or destroy as many mesothelioma cells as possible in the abdomen. French researchers studied the evolution of the procedure over time. They discovered that it has improved. As a result, people with peritoneal cancers like malignant mesothelioma are living longer. Cytoreductive Surgery for Mesothelioma Peritoneal mesothelioma causes tumors on the peritoneal membrane that lines the abdomen. Like other forms of mesothelioma, the cause is usually asbestos exposure. Cytoreductive surgery (CRS) is an operation to remove tumors from the abdomen. Mesothelioma tumors may be confined to the peritoneal membrane, or … Continue reading CRS/HIPEC Procedure Has Improved Over Time, Study Finds
Prognostic Value of PET/CT in Pleural Mesothelioma Patients
New data highlights the prognostic value of PET/CT scans for patients with malignant pleural mesothelioma. Pleural mesothelioma is a rare malignancy with a poor prognosis. But some patients tend to do better than others. Scientists are always looking for better ways to predict which patients will respond best to which treatment. A new Turkish study focused on the prognostic value of scans that measure tumor volume and metabolic activity. They conclude that PET/CT is a valuable way to predict mesothelioma outcomes. Doctors can use the information to help plan for chemotherapy or surgical treatment. How PET/CT Scans Work Doctors have been aware of malignant mesothelioma since the 1930s. That is when it first started appearing among asbestos workers. But there … Continue reading Prognostic Value of PET/CT in Pleural Mesothelioma Patients
Mesothelioma Subtypes Often Misclassified by Biopsy
Pleural biopsy is not perfect when it comes to telling the difference between the three mesothelioma subtypes. But misclassification could lead to shorter survival. That is the conclusion reached by top mesothelioma researchers in Brescia, Italy. They compared autopsy records from 134 Italian mesothelioma patients. The patients were either shipyard workers or their spouses. The researchers found that the mesothelioma subtypes identified from biopsy tissue were incorrect a large percent of the time. Misclassification matters because it impacts which mesothelioma treatments doctors choose. The Three Mesothelioma Subtypes Pleural mesothelioma is an aggressive malignancy on the lung lining. It is caused by exposure to asbestos. Mesothelioma cells fall into three mesothelioma subtypes based on certain cellular characteristics. Pleural mesothelioma is notoriously … Continue reading Mesothelioma Subtypes Often Misclassified by Biopsy
Long-Term Mesothelioma Survival with ONCOS-102
The makers of the immunotherapy treatment ONCOS-102 have released promising new data on its ability to promote long-term mesothelioma survival. The report came less than two weeks after ONCOS-102 got FDA approval to fast-track its development. ONCOS-102 is an investigational treatment made from a modified virus. The virus helps the treatment target mesothelioma cells while leaving healthy cells alone. The new long-term mesothelioma survival data shows half of people on ONCOS-102 and chemotherapy have lived for 21 months. And the study is not over yet. Typical survival with standard mesothelioma chemotherapy is about a year. Targovax says the data shows how valuable ONCOS-102 could be for patients with this rare but aggressive malignancy. Standard of Care for Pleural Mesothelioma Pleural … Continue reading Long-Term Mesothelioma Survival with ONCOS-102
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."
Get your free copy of
“Surviving Mesothelioma” Today!